OSCR Stock Recent News

Oscar Health's tech-driven flywheel is shrinking costs, boosting retention, and driving rapid membership growth, validated by 42% revenue growth and record profitability in Q1 2025. Platform revenue from +Oscar and data licensing is compounding faster than insurance premiums, creating a high-margin, SaaS-like earnings stream that legacy insurers can't match. Favorable policy trends and employer adoption of ICHRAs funnel incremental lives to Oscar at low acquisition cost, while Oscar's consumer-centric UX and provider partnerships deepen its moat.

In the latest trading session, Oscar Health, Inc. (OSCR) closed at $20.42, marking a -3.77% move from the previous day.

Oscar Health, Inc. is undervalued despite a recent rally, with strong growth and earnings potential as a tech-driven disruptor in health insurance. The company boasts accelerating revenues, improving profitability, a robust balance sheet, and positive cash flow, supporting further upside. ACA enrollment growth, favorable ICHRA trends, and industry disruption position Oscar for continued success and margin expansion.

Wall Street thinks health insurance is boring. That's exactly why Oscar Health (OSCR 16.70%) could be your best contrarian play in 2025.

In this video, I will cover Oscar Health (OSCR 16.70%) and why I find this a compelling investment opportunity. Watch the short video to learn more, consider subscribing, and click the special offer link below.

Oscar Health is uniquely undervalued, combining 42% revenue growth with profitability and a low EV/Sales multiple, making it a standout in the market. The company's $2.23B cash position versus its $4.8B market cap highlights significant balance sheet strength and downside protection. ICHRA market expansion offers massive upside potential, but regulatory risks and limited pricing power cap long-term sustainability.

Oscar Health (OSCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

When it comes to healthcare stocks, many investors pay attention to the usual suspects: Eli Lilly, Novo Nordisk, CVS Health, or Johnson & Johnson. These companies have built up enormous brand equity thanks to blockbuster drugs and widely recognized pharmacy management services.

Oscar Health is leveraging technology and AI to disrupt the health insurance industry, driving strong membership growth and improving operational efficiency. Financials are rapidly improving: premium revenue growth outpaces claims, margins are expanding, and the company has turned profitable with a strong balance sheet. Analysts project massive EPS growth through 2027, making OSCR undervalued compared to peers and offering significant upside for risk-tolerant investors.

Oscar Health, Inc. (OSCR) reached $14.34 at the closing of the latest trading day, reflecting a +1.34% change compared to its last close.